Loading…
Summit Therapeutics Inc. is projected to rise to $17.06 by 2027, a +27% move from its current price of $13.44. SMMT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $12.97 | $13.44 | $13.94 | +0.03% |
| Aug 2 | $12.78 | $13.45 | $14.15 | +0.05% |
| Aug 3 | $12.63 | $13.45 | $14.32 | +0.08% |
| Aug 4 | $12.52 | $13.45 | $14.46 | +0.11% |
| Aug 5 | $12.41 | $13.46 | $14.59 | +0.13% |
| Aug 6 | $12.32 | $13.46 | $14.71 | +0.16% |
| Aug 7 | $12.24 | $13.46 | $14.82 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.24 | $13.46 | $14.82 | +0.18% |
| Week 2 | $11.78 | $13.49 | $15.44 | +0.37% |
| Week 3 | $11.45 | $13.51 | $15.95 | +0.55% |
| Week 4 | $11.18 | $13.54 | $16.40 | +0.74% |
| Week 5 | $10.95 | $13.56 | $16.80 | +0.92% |
| Week 6 | $10.75 | $13.59 | $17.18 | +1.11% |
| Week 7 | $10.57 | $13.61 | $17.54 | +1.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Summit Therapeutics Inc. is a biopharmaceutical company focused on discovery, development, and commercialization of medicinal therapies that aim to benefit patients, physicians, caregivers, and society. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. Summit markets its products in the United States, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Summit Therapeutics Inc. (SMMT) is currently trading at $13.44 per share and has a market capitalization of $10.72B. It is ranked 821 by market cap and sits among biotech peers with a broad international footprint.
A major floor 21.2% below — a decisive break under it would weaken the trend.
The nearest floor, 6.6% below — buyers have tended to step in here.
The nearest ceiling, 18.5% above — a clean break opens room to run.
A major ceiling 96.3% above — clearing it would confirm fresh momentum.
Key SMMT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SMMT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.11 | Buy | $13.30 | Buy |
| MA 10 | $13.72 | Sell | $13.66 | Sell |
| MA 20 | $14.52 | Sell | $14.10 | Sell |
| MA 50 | $14.83 | Sell | $15.04 | Sell |
| MA 100 | $16.82 | Sell | $16.04 | Sell |
| MA 200 | $17.10 | Sell | $17.18 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.71 | Neutral |
| Stoch RSI (14) | 46.37 | Neutral |
| CCI (20) | -75.53 | Neutral |
| Williams %R (14) | -69.52 | Info |
| MACD (12,26,9) | -0.14 | Sell |
| ROC (12) | -13.12 | Sell |
| Bollinger %B (20,2) | 0.24 | Neutral |
| Stochastic %K (14) | 30.48 | Neutral |
| TRIX (15) | -0.32 | Sell |
| Awesome (5,34) | -1.23 | Sell |
| Ultimate (7,14,28) | 36.88 | Neutral |
| Momentum (10) | -0.32 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 12.50 | Buy |
| ADX (14) | 16.50 | Neutral |
| ATR (14) | 0.47 | Info |
The 30-day technical picture is mixed, with NEUTRAL sentiment and an RSI of 40. The stock trades with a 50-day simple moving average at $14.83 and a 200-day simple moving average at $17.10, placing the price below both moving averages. Key levels to watch are support at $12.55 and resistance at $15.93, framing a near-term range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.55 | $13.44 | $18.38 | 0% | Neutral | |
| $13.20 | $17.06 | $23.54 | +27% | Bullish | |
| $13.68 | $18.37 | $26.58 | +37% | Bullish | |
| $14.44 | $20.03 | $30.07 | +49% | Bullish | |
| $14.35 | $20.49 | $31.71 | +52% | Bullish | |
| $15.41 | $22.58 | $35.89 | +68% | Bullish | |
| $19.97 | $30.01 | $48.83 | +123% | Bullish | |
| $21.95 | $33.76 | $56.11 | +151% | Bullish | |
| $22.94 | $36.07 | $61.14 | +168% | Bullish | |
| $22.52 | $36.18 | $62.44 | +169% | Bullish | |
| $34.76 | $61.65 | $114.68 | +359% | Bullish | |
| $52.84 | $112.08 | $232.10 | +734% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $12.55 | $13.44 | $15.72 | +0.00% |
| August 2026 | $11.68 | $13.80 | $16.76 | +2.68% |
| September 2026 | $11.52 | $13.77 | $17.01 | -0.24% |
| October 2026 | $11.85 | $14.29 | $17.91 | +3.82% |
| November 2026 | $12.13 | $14.73 | $18.67 | +3.09% |
| December 2026 | $11.74 | $14.36 | $18.38 | -2.52% |
Click any year to see its month-by-month SMMT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Summit Therapeutics Inc.'s 2026 outlook centres on $13.44, within a $12.55 to $18.38 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, SMMT could reach as high as $23.54, with a base case around $17.06 and support toward $13.20 — roughly +27% from $13.44. Buyers look set to stay in control over this stretch.
Expect SMMT to range from $13.68 to $26.58 through 2028. The $18.37 average target implies a +37% move from current prices. That is up +8% on the projected 2027 average. Momentum favours further upside here.
The SMMT price prediction for 2029 points to an average of $20.03 (low $14.44, high $30.07) — a potential gain of +49% on today's $13.44. Buyers look set to stay in control over this stretch.
In 2030, SMMT is projected to trade between $14.35 and $31.71, averaging $20.49 — a potential gain of +52% from today's $13.44. That is up +2% on the projected 2029 average. Momentum favours further upside here.
Summit Therapeutics Inc.'s 2031 outlook centres on $22.58, within a $15.41 to $35.89 range. That is up +10% on the projected 2030 average. That marks a +68% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, SMMT could reach as high as $48.83, with a base case around $30.01 and support toward $19.97 — roughly +123% from $13.44. Momentum favours further upside here.
Expect SMMT to range from $21.95 to $56.11 through 2033. The $33.76 average target implies a +151% move from current prices. That is up +12% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The SMMT price prediction for 2034 points to an average of $36.07 (low $22.94, high $61.14) — a potential gain of +168% on today's $13.44. Momentum favours further upside here.
In 2035, SMMT is projected to trade between $22.52 and $62.44, averaging $36.18 — a potential gain of +169% from today's $13.44. That is up 0% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Summit Therapeutics Inc.'s 2040 outlook centres on $61.65, within a $34.76 to $114.68 range. That is up +70% on the projected 2035 average. That marks a +359% change versus current levels. Momentum favours further upside here.
By 2050, SMMT could reach as high as $232.10, with a base case around $112.08 and support toward $52.84 — roughly +734% from $13.44. Buyers look set to stay in control over this stretch.
Investing $1,000 in SMMT today (≈ 74.404762 SMMT) could be worth
$8,339.05
+$7,339.05 (+734%) by 2050 · US Dollar
Based on the average projected SMMT price of $112.08 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SMMTwould be worth at today's price.
$1,000 invested in SMMT on Jul 30, 2025 (≈ 37.509378 SMMT) would be worth
$504.13
-$495.87 (-49.6%) today · 0.50× · US Dollar
Based on a SMMT entry price of $26.66 vs. today's $13.44.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $14.98 | $897.2 | -10.3% |
| 1 month ago | $14.57 | $922.44 | -7.8% |
| 3 months ago | $16.11 | $834.01 | -16.6% |
| 6 months ago | $14.48 | $928.18 | -7.2% |
| 1 year ago | $26.66 | $504.13 | -49.6% |
| All time (5.0y) ago | $7.75 | $1,734.19 | +73.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SMMT forecast.
Our base-case forecast reaches $27.00 around 2032.
Implied market cap at $27.00: $21.54B
The multi-year forecast shows a bullish trajectory from 2027 onward, with the average price rising from $13.44 in 2026 to higher levels through 2030 and beyond. Notable milestones include a 2027 average of $17.06 and a 2030 average of $20.49, with a 2032 average of $30.01 and a 2040 average of $61.65, culminating in a 2050 average of $112.08. Return-on-investment projections rise from 0% in 2026 to 52.5% in 2030, 358.7% in 2040, and 733.9% in 2050, all with a bullish sentiment in 2030 and beyond.
These figures illustrate a strong long-term upside but are estimates, not guarantees, and depend on market factors and execution.
Tap a question to reveal the answer.
Avg $20.49; Min $14.35; Max $31.71; ROI 52.5%; Sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward, with the average price rising to $20.49 by 2030 and to $112.08 by 2050, and ROI advancing to 52.5% by 2030 and 733.9% by 2050. These are estimates, not guarantees.
Yes, the forecast max for 2033 is $56.11, which exceeds $50; the 2032 max is $48.83, so a $50 level is possible in 2033 within the predicted range.
Current price $13.44; Market cap $10.72B.
Avg $61.65; Min $34.76; Max $114.68; ROI 358.7%; Sentiment BULLISH.
Summit Therapeutics Inc. Community Discussion
0Share your Summit Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.